Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab in Metastatic Merkel Cell Carcinoma
NCT01913691Phase 2Withdrawn
- Sponsor
- National Cancer Institute
- Start
- Jul 2013
- Primary completion
- Feb 2014
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of ipilimumab in Merkel cell carcinoma (MCC), sponsored by National Cancer Institute. Planned start Jul 2013; status: withdrawn.
02
Drugs
ipilimumab
03
Conditions
Merkel cell carcinoma (MCC)
Beyond the preview
Go deeper on NCT01913691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01913691.